the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, informs its shareholders that the Annual Ordinary and the Extraordinary General Meeting will be held on Wednesday 13 June 2018 at 4pm at 37 Rue Auguste Piccard, 6041 Gosselies, Belgium. If the attendance quorum is not reached at this extraordinary shareholders’ meeting, a second shareholders’ meeting will be convened and held on 9 July 2018 as of 4pm, at rue Auguste Piccard 37, 6041 Gosselies.
The notice for the meetings, including the agenda of the day as well as the motions to vote, will be published in L’Echo on 12 May 2018 and in the Belgian Official Gazette on 14 May 2018.
The documents and preliminary information concerning these meetings are being made available to the shareholders and can be consulted on the website of the Company: www.bonetherapeutics.com, under the section Investors / Shareholders meeting, in compliance with the applicable law and regulations.
It is also possible to receive the documents without charge upon simple request by email to email@example.com or by telephone on +32 (0)71 12 10 01. Finally, the documents are available at the Company’s headquarters: 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.
Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
The Company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.